7 бет - Ең жақсы Бас миының МРТ дәрігерлері - ЖОҒ-236 дәрігерлер

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr. LV Xiao Jun is the Executive Director of the Department of Medical Oncology. He is a national expert in psycho-oncology and has 30 years of clinical experience. He previously served at the First Affiliated Hospital of Xiamen University. He is a recognized expert in cancer treatment and lung cancer care in Fujian Province.

Clinical focus: comprehensive care for solid tumors, including lung, breast, and gastrointestinal cancers; palliative care in oncology; and screening and treatment for psychological distress.

Appointments: Standing Committee Member (third term), Psycho-Oncology Committee, Chinese Anti-Cancer Association; Standing Committee Member (third term), Lung Cancer Committee, Fujian Anti-Cancer Association.

Dr. Yan Zhi Ping is the Director of the Radiology Department at Xiamen Humanity Hospital. He graduated from the First Military Medical University. He has authored more than 30 papers. He has edited and contributed to several monographs. He received a Fujian Provincial Third Prize for Science and Technology Progress and two Xiamen Municipal Second Prizes. His expertise includes CT and MRI of the central nervous system, musculoskeletal system, thoracic, and abdominal diseases. He also focuses on cerebral functional imaging. He is skilled in the early diagnosis and differential diagnosis of lung cancer and brain tumors.

Appointments: Standing Committee Member of the Radiology Branch of the Fujian Association of Integrative Medicine. Standing Committee Member of the Fujian Radiological Society. Vice Chairman of the Xiamen Radiological Society. Vice Chairman of the Radiology Branch of the Xiamen Medical Doctor Association. Deputy Director of the Xiamen Radiology Quality Control Center.

Dr. Nurperi Gazioglu is a neurosurgeon. She trained at Istanbul University Cerrahpaşa Faculty of Medicine. She earned her MD in 1984 after study from 1978 to 1984. She completed neurosurgery training from 1986 to 1993. Her 1993 dissertation examined “Fetal Hypophysis Transplantation Under the Renal Capsule in Rats.”

She completed advanced courses in endoscopic pituitary surgery (2005, 2007, 2008) and endoscopic lumbar disc surgery (2007). She also trained in molecular genetics for clinicians (2003) and CME with the World Federation of Neurology (2002). She studied epilepsy surgery focused on insular–hippocampal anatomy (1999) and thoracolumbar trauma (1998). She attended the EANS European Neurosurgery Course (1988). Her clinical training includes observerships at APHP Necker–Enfants Malades and Hôpital Lariboisière in 1991. She completed an internship there in 1999.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Yang Seyeon is a neurosurgeon specializing in ischemic stroke, intracerebral hemorrhage, cerebral aneurysm, moyamoya disease, carotid artery stenosis, vascular dizziness, and head trauma. Dr. Yang is the Head of the Department of Neurosurgery at Naeun Hospital.

Dr. Yang graduated from The Catholic University and earned a Master of Medicine. Dr. Yang completed an internship and a neurosurgery residency at the Catholic Medical Center. Dr. Yang served as a neurosurgery fellow at Uijeongbu St. Mary’s Hospital and worked at its Regional Trauma Center. Dr. Yang also served as a dedicated neurosurgery specialist.

Dr. Yang served as a Clinical Assistant Professor of Neurosurgery at Uijeongbu St. Mary’s Hospital. Dr. Yang also served as Head of Neurosurgery at G‑Sam Hospital.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Zuhal Cakmak Peksen is a Family Medicine Specialist since 2017. She earned her MD from Çukurova University in 2010. She completed specialty training at Yüzüncü Yıl University between 2013 and 2017. She is currently studying for a bachelor’s degree in Health Management at Anadolu University (2024–present).

She has 15 years of clinical practice (2010–2025) across 8 institutions. Her experience includes research in Family Medicine (2013–2017) and work at several Family Health Centers. Since 2020, she has served at TOKİ Avrupa Family Health Center in Gaziosmanpaşa, Istanbul.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr. Halil Can is a Professor of Neurosurgery (2025; Associate Professor 2020). He completed neurosurgical training at Istanbul University–Istanbul Faculty of Medicine in 2007. His clinical focus includes endoscopic and microsurgical spine surgery for fractures, tumors, and degenerative disease; advanced pain procedures; endoscopic skull base and pituitary surgery; and neurovascular, neuro-oncologic, and peripheral nerve surgery.

He has 21 international peer-reviewed papers (SCI/SSCI). Topics include cadaveric morphometry of Kambin’s triangle and the transforaminal triangular working zone, lumbar arterial and anterior approach anatomy, and an in vitro test of a new lumbar fixation device.

His clinical studies include a single-team series of 81 posterior circulation aneurysms, with 13 flow-diversion cases. He also reported five spinal cavernous malformation cases. He conducted Phase I safety and feasibility stem-cell trials in pediatric hypoxic-ischemic encephalopathy and in chronic complete spinal cord injury.

Dr. Ali Osman Mucuoglu is a neurosurgeon. He completed his neurosurgery residency at Dokuz Eylül University from 2013 to 2019 after graduating from Eskişehir Osmangazi University in 2012 (2005–2012). He worked at Dokuz Eylül University and Muş State Hospital from 2019 to 2021. He has practiced at Atlas University Hospital since 2021.

He has five publications. These include a case report in the International Journal of Surgery Case Reports that has been cited seven times. He also reported on 3D printer‑assisted transsphenoidal hypophysectomy and on emergency minimally invasive intracerebral hemorrhage (ICH) surgery. He delivered an oral presentation at the 33rd Turkish Neurosurgical Society Congress in 2019.

He is a member of the Turkish Neurosurgical Society, the European Association of Neurosurgical Societies, and the Istanbul Chamber of Medicine. His advanced training includes spinal surgery courses in 2016 and 2017, the European Training Course on Head Injury and Functional Neurosurgery in 2017, and Surgical Neuroanatomy in 2017. He also holds an animal experimentation certificate from 2016.

Dr. Fatma Gulhan Sahbaz is a neurologist. She graduated from Manisa Celal Bayar University Faculty of Medicine. She completed her neurology residency at SBÜ Istanbul Kartal Dr. Lütfi Kırdar Training and Research Hospital. Dr. Sahbaz has served as Clinic Chief at Afyonkarahisar State Hospital. She currently practices at İzmir Ekonomi University Medical Point Hospital.

She treats many neurological conditions, including Alzheimer’s disease, ALS, epilepsy, cerebrovascular diseases, brain tumors, movement disorders, and headaches. Dr. Sahbaz is experienced in advanced treatments such as acute stroke intervention, deep brain stimulation, IVIG therapy, and botulinum toxin injections.

She is a member of the Turkish Neurology Society, International Parkinson and Movement Disorder Society, and European Academy of Neurology.

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Name and Surname: Süleyman OFLU

Place and Year of Birth: Trabzon – 1963

Academic Title: Expert. Dr.

Foreign Language: English

Education Trabzon University Faculty of Medicine Osmangazi University Faculty of Medicine

Work Experience

Karaman State Hospital 2000-2004

Hitit University Çorum Erol Olçok Training and Research Hospital 2004 - 2021

Kırıkkale Private Life Hospital 2021-2023

Treatment Areas

Depression

Anxiety Disorders

Schizophrenia

Bipolar Disorder

Eating Disorders

Obsessive Compulsive Disorder (OCD)

Panic Disorder

Post Traumatic Stress Disorder

Social Anxiety Disorder

Borderline Personality Disorder

Narcissistic Personality Disorder

Antisocial Personality Disorder

Autism Spectrum Disorder

Attention Deficit Hyperactivity Disorder

Panic Attack

Personality Disorders Addiction and Substance Use Disorders

phobias

EDUCATION:

2015

Uludag University, Ophthalmology

2008

Eskisehir Osmangazi University, Faculty of Medicine

2001

Kırıkkale Science High School, Numerical

EXPERIENCE:

2019 Gazi University Faculty of Medicine Ophthalmology (Vitreo-Retinal Surgery and Medical Retina Fellowship)

2016 SBÜ Zekai Tahir Burak EAH (Retinopathy of Prematurity Fellowship)/

2015 - 2023 Kocaeli Derince Training and Research Hospital

2023 - Medipol University Pendik Hospital

Education: 

Degree                       Program                                             University                   Year

Bachelor                     Medical Sciences                               İstanbul University     1995

Master Degree           Medical Sciences                               İstanbul University     1997

Doctorate and expertise in medicine

Istanbul Faculty of Medicine, Department of Neurology     İstanbul University     2004

Assistant professor     

İstanbul Bilim University, Faculty of Medicine, Department of Neurology İstanbul Bilim University        2009

Associate professor

İstanbul Bilim University, Faculty of Medicine, Department of Neurology İstanbul Bilim University        2011

Clinical Neurophysiology Subspecialty          

İstanbul Bilim University, Faculty of Medicine, Department of Neurology İstanbul Bilim University        2011

PhD Thesis:

INVESTIGATION OF ANTI-GANGLIOSIDE AND ANTI-GLUTAMIC ACID DECARBOXYLASE ANTIBODIES IN JUDICIAL MYOCLONIC EPILEPSY AND INVESTIGATION OF SUBCLINIC ANTERIOR HORN INVOLVEMENT BY ESTIMATE MOTOR UNIT COUNT METHOD-2002

Experience

Research Assistant 

Department of Neurology, Istanbul Faculty of Medicine, Istanbul University        1998-2004

Specialist

Şişli Florence Nightingale Hospital, Department of Neurology       2004-2009

Assistant Professor

Istanbul Bilim University, Faculty of Medicine, Department of Neurology 2009-2011

Assoc. Prof.     

Şişli Florence Nightingale Hospital Department of Neurology 

İstanbul Florence Nightingale Hospital 

Memberships to Scientific Organizations:

Turkish Medical Association

Turkish Neurology Association

Turkish Association for Combating Epilepsy

Turkish Clinical Neurophysiology EEG-EMG Association

Association of Child Neurology and Neuroimmunology

Awards:

Clinical Neurophysiology Congress (Antalya-2013): First prize for the poster paper titled "Continuous Video-EEG Monitoring Findings and Clinical, Laboratory and Imaging Characteristics of Patients Monitored in the Neurology Intensive Care Unit Due to Alertness Defect"

National Epilepsy Congress (Muğla-2012): "Does Semiology Tell Us the Origin of Seizures Consisting Mainly of Alteration of Consciousness?" Kenan Tükel publishing award for his publication

National Epilepsy Congress (Izmir- 2008): First prize in the field of epilepsy congress publications with the publication titled "Reduced axon number in Juvenile Myoclonic Epilepsy demonstrated by motor unit number estimation analysis"

National Epilepsy Congress (Ankara- 2004): First prize in the field of epilepsy congress publication with the publication titled "No association of anti-gm1 and anti-gad antibodies with juvenile myoclonic epilepsy"

Turkish Clinical Neurophysiology EEG-EMG Association, 19th National Clinical Neurophysiology EEG-EMG Congress (Trabzon-2002): Congress publication award for the publication titled "Epileptic seizures in Behçet's disease".

Turkish Scientific and Technical Research Council scientific publications incentive award-2002: (With the publication titled "Epileptic Seizures In Behçet's Disease")

Turkish Neurology Association, 38th National Neurology Congress - 2002: Second prize for the oral presentation titled "Investigation of subclinical anterior horn involvement in juvenile myoclonic epilepsy with the estimated motor unit number method".

Turkish Epilepsy Association and Sanofi Pharma Scientific Research Project Support Award - 2001: "Investigation of anti-ganglioside antibodies in juvenile myoclonic epilepsies" thesis project.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Кәсіби тәжірибе

2006 жылдан бері Мадридтегі Quironsalud Университеттік Ауруханасының және Ruber Juan Bravo Ауруханасының Неврология бөлімінің бастығы болып қызмет атқарады.

Мадридтегі Еуропалық Университеттің Биомедициналық Ғылымдар факультетінің Медицина профессоры, Медицина Ғылымдары Профессорының ұлттық аккредитациясына ие (ANECA-дан берілген).

Медицина докторы, Мадридтегі Complutense университеті (UCM). Көрнекті докторлық диссертацияға арналған сыйақы (UCM, 2004): көптеген склерозда қоршаған орта факторы ретінде адамның герпес вирусы 6-мен байланысын зерттеу.

Ғылыми қоғамдарға мүшелік

Quironsalud Мадридтегі Нейроғылымдар бойынша ұлттық және халықаралық жетекші зерттеуші (маусым 2015 – қазіргі уақытқа дейін)

Мадридтегі Quironsalud Университеттік Ауруханасының Зерттеу Комитетінің Президенті (2012 жылдан қазіргі уақытқа дейін).

Сан-Карлос Клиникалық Ауруханасының Зерттеу Комитетінің мүшесі (2012-2015).

Мадридтегі Complutense университетінің Медицина факультетінің Кеңес мүшесі (2011-2015).

Зерттеу және оқыту

100 ұлттық және халықаралық клиникалық сынақтардың бас зерттеушісі.

Carlos III Денсаулық Институтының 7 FIS зерттеу жобасы (соңғы 5 бас зерттеуші ретінде).

Жеке қорлардан 10 жоба, бәсекеге қабілетті негізде алынған (7 бас зерттеуші ретінде).

Ол 949,917 жалпы әсер ету факторына және 4,552 сілтеме иеленген 139 халықаралық мақаланың авторы. H-факторы 34 (2018) болған 38 кітап пен кітап тараулары бар.

Оның басылымдары зерттеулерге ең ғаламдық әсер ететін журналдарда ерекшеленіп тұрады, мысалы, New England Journal of Medicine және Lancet.

Др. Рафаэль Арройо түрлі Конгрестерде 300-ден астам халықаралық және ұлттық баяндамалар жасаған.

Білім :

Мадридтегі Еуропалық Университеттің Биомедициналық Ғылымдар факультетінің Медицина профессоры және Медицина Ғылымдары Профессорының ұлттық аккредитациясына ие (ANECA-дан берілген).

Dr. Mehmet Tonge is a neurosurgeon with expertise in Stereotactic and Functional Neurosurgery. He specializes in MR Guided Focused Ultrasound, deep brain stimulation, Gamma Knife Radiosurgery, and surgery for movement disorders, pain, and spasticity.

Dr. Tonge has published 32 articles in international and national journals and written 12 book chapters. He has presented 92 oral and poster presentations and delivered 41 invited lectures. He completed a Deep Brain Stimulation Fellowship at Maastricht University and finished the 4-year EANS training cycle. Dr. Tonge is known for his research and clinical work in functional neurosurgery.

Dr Romero Imbroda is an academic of the Royal Academy of Medicine of Eastern Andalusia and a Fellow of the European Board of Neurology, as well as a Member of the Board of Directors of the

Andalusian Society of Neurology. He combines his medical practice with his teaching role at the University of Granada, where he is a Lecturer and has been a Member of the Internal Residential Doctor Assessment Committee in Melilla until 2017.

He is the author of several national and international scientific publications. He has also participated in research projects associated with treatments for multiple sclerosis.

Professional Experience:

• 2020: President of the Andalusian Society of Neurology

• 2019: Head of the Units at the Quirónsalud Malaga and Marbella Hospitals

• 2017-2021: Neurologist at the Regional Malaga University Hospital.

• 2016-2017: Lecturer at the University of Granada.

• 2009-2017: Neurologist at the Imbrain Neuroscience Clinic. Melilla.

• 2009-2017: Neurologist at the Melilla Hospital.

• 2008-2009: Neurologist at the Virgen de las Nieves Hospital. Granada.

• 2004-2008: Neurologist at the Carlos Haya Hospital. Malaga.

Academic Training:

• 2017: Innovation and Leadership in Neurology. Business Institute. Madrid.

• 2014: Educational Commission for Foreign Medical Graduates. United States.

• 2011-2012: Management of Integrated Health Services. ESADE. Madrid.

• 2010: Neurologists for the Future. Spanish Neurology Society.

• 2010: Master in Tissue Engineering. University of Granada.

• 2010: Doctorate at the University of Granada. Summa Cum Laude. 2010.

• 2004-2008: Neurology specialist at the Carlos Haya Hospital. Malaga.

• 1997-2003: University Graduate in Medicine at the University of Granada.

The Neurology Unit of the Quirónsalud Marbella Hospital specialises in the study and treatment of conditions associated to the nervous system, the brain, the spinal cord, the peripheral nerves and the muscles. We have the most advanced technology that enables us to make accurate and personalised diagnoses and treatments in the study of patients with complex diagnoses and treatments (MRI, CT scan,electroencephalogram, transacranial doppler ultrasound, cerebral arteriogramand neuropschycological testing).

We offer our patients highly-specialised treatments for cerebrovascular and neuromuscular diseases, Parkinson's Disease, headaches and migraine, epilepsy, multiple sclerosis, peripheral neuropathies, infections of the nervous system, movement disorders, dementia and other cognitive conditions, paediatric neurology, sleep disorders, tumours and complications deriving from injuries to the spine and the head.